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92 Investigation of a shared strain of Burkholderia cenocepacia
isolated from two CF siblings
A. Salmon1, M. Shinoy2, D. Keating1, R. Dennehy2, M. Callaghan2, S. McClean2,
K. Schaffer1. 1St. Vincent’s University Hospital, Microbiology Department, Dublin,
Ireland; 2Institute of Technology Tallaght, Centre of Microbial Host Interactions,
Dublin, Ireland
Two siblings with CF attending the CF clinic in SVUH are both infected with
Burkholderia cenocepacia IIIA. In one host the organism remains conﬁned to the
lungs while in the other host, the organism has been isolated both from lungs and
blood cultures during exacerbation.
Objectives:
1. To investigate whether there are any genetic differences between the sputum
isolates from both hosts and between the blood and sputum isolates in the one
host.
2. To examine differences in the pathogenicity of these blood and sputum isolates
over time in lung epithelial cells, in vitro.
Methods: Serial Burkholderia cenocepacia isolates were collected from the two
siblings.
• Restriction Fragment Length Polymorphism (RFLP), pulse ﬁeld gel electrophore-
sis (PFGE) and recA sequencing was carried out on all isolates.
• Intracellular invasion of the isolates into CF bronchial epithelial cells (CFBEs)
was examined by antibiotic protection assay. Translocation across polarised cell
monolayers was also examined.
Conclusions:
• We conﬁrmed the genomovar type of the organism by both RFLP and recA
sequencing. All isolates were identical by PFGE typing. RecA sequences did not
show any differences. Additional molecular investigations on isolates from both
hosts will include analysis of seven house keeping genes by MLST to look for
any genetic divergences.
• Comparison of respiratory and blood isolates invasion into CFBE cells isolates is
ongoing. We will also compare the proteome of these isolates by MALDI-TOF,
to examine if differential protein expression is involved in the different infection
proﬁles in the two siblings.
93 Do swarming and twitching motility in Pseudomonas aeruginosa
have a role in early infection of cystic ﬁbrosis airways and in the
enhanced transmissibility of epidemic strains?
C. Doherty1, L. Doherty1, J.R. Govan1. 1University of Edinburgh, Centre for
Infectious Diseases, Edinburgh, United Kingdom
Objectives: We investigated the hypothesis that twitching and swarming motility in
Pseudomonas aeruginosa have a role in early CF lung infection and in the enhanced
transmissibility of epidemic strains.
Methods: Three panels of P. aeruginosa isolates were investigated. (A) 46 isolates
from natural environments; (B) 21 ﬁrst sputum isolates obtained during longitudinal
studies. (C) 17 isolates representing epidemic strains. Bacterial twitching and
swarming were investigated using soft agar and other appropriate conditions.
Bacterial clonality was excluded by pulsed-ﬁeld gel electrophoresis.
Results: Pseudomonas aeruginosa PAO1, used as a control, showed reproducible
twitching measuring 23mm. The majority of environmental isolates (37/46, 80%)
also exhibited twitching (range 5−23mm, mean 15.1mm). Amongst ﬁrst isolates,
twitching was observed in 11/21 isolates (52%; range 5−27mm, mean 16mm).
In the 17 epidemic strains, twitching was restricted to 4/17 isolates (24%, range
4−16mm, mean 8.8mm). Swarming motility was measured qualitatively by the
presence or absence of tendril-like growth originating from the point of stab
inoculation. The percentage of isolates which exhibited swarming in panels A,
B and C were 24/46 (52%), 4/21 (19%) and 0/17 (0%) respectively. Twitching and
swarming were independent of mucoidy or antibiotic resistance.
Conclusion: Twitching and swarming motility appear to have a negative inﬂuence
on initial Pseudomonas infection of CF airways and as an explanation for enhanced
transmissibility. Since these forms of motility are considered to play an important
role in other respiratory infections our ﬁndings are unexpected and merit further
study.
94 Statins, a widely used cholesterol-lowering drug, modulate key
virulence behaviour of Pseudomonas aeruginosa
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Statins are a class of medicine which reduces cholesterol biosynthesis by in-
hibiting the enzyme 3-hydroxy-3-methylglutaryl-CoA reductase. Although known
pleiotropic effects of statins include anti-inﬂammatory and anti-microbial activity,
the effect of statins on bacterial behaviour has not yet been fully investigated.
We therefore investigated the effect of simvastatin [SIM], lovastatin [LOV], and
mevastatin [MEV] on a range of key virulence factors of Pseudomonas aeruginosa,
the main pathogen associated with mortality and morbidity in cystic ﬁbrosis [CF]
patients. Firstly, anti-microbial activity of statins on the P. aeruginosa model
strains PAO1 and PA14 was assessed. None of the statins affected the growth
of P. aeruginosa, and they did not have an impact on quorum sensing and type
three secretion. However, statins reduced motility and bioﬁlm formation, which
are crucial factors involved in the colonisation and persistence of infections in the
lungs of CF patients. Altogether, these data demonstrate that statins have a speciﬁc,
targeted effect against P. aeruginosa. Further studies will focus on elucidating the
molecular mechanism by which statins alter Pseudomonas pathogenicity. The dual
inﬂuence of statins on inﬂammation and pathogen behaviour highlights the potential
for their use in the development of innovative therapeutic strategies.
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chronic infection or colonization?
V. Rodriguez-Nava1, A.-M. Freydie`re2, C. Segonds3, M. Perouse de Montclos4,
H. Meugnier2, O. Fendrich1, E. Bergeron1, S. Chyderiotis2, J. Karsenty4,
G. Bellon5, P. Reix5, R. Nove-Josserand4, M. Murris6, F. Bre´mont6,
L. Tetu6, S. Durupt4, I. Durieu4, P. Boiron1, J. Freney1, F. Vandenesch2,
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Objective: Clinical impact of Nocardia isolated in patients with cystic ﬁbrosis
(CF patients).
Method: Nocardia spp. were isolated from the lungs of 10 CF patients (6 male
and 4 female, aged 7 to 46) in the CF Centers of Lyon and Toulouse, France,
between 1997 and 2011. Clinical data (risk factors, clinical status at ﬁrst recovery,
symptoms, Shwachman and Brasﬁeld scores, FVC, FEV1, antimicrobial therapy)
as well as bacteriological data (number of Nocardia-positive samples, antibiotic
susceptibility, associated pathogens) were analyzed.
Results: Five species of Nocardia were identiﬁed: N. transvalensis (1), N. as-
teroides (1), N. abscessus (2), N. farcinica (2) and N. cyriacigeorgica (4). Two
of the ten patients presented with exacerbations at ﬁrst recovery. Eight patients
were more or less symptomatic with few rales to severe dyspnea, purulent sputum
or nodules. In seven out of the 10 samples, Nocardia was associated with other
pathogens: Staphylococcus aureus (6 samples), Pseudomonas aeruginosa (3 sam-
ples), Stenotrophomonas maltophilia (2 samples), Streptococcus pneumoniae and
Haemophilus inﬂuenzae (1 sample). Yeasts and molds were also observed. In 8 of
the 10 patients, several samples (2 to 5) were Nocardia positive. Cotrimoxazole,
b-lactams, aminoglycosides, linezolide, quinolones were used for treatment, sys-
tematically or in case of exacerbation, as single agents or in combination and for
durations depending on the severity of symptoms.
Conclusion: The role of Nocardia in CF patients is poorly studied. Our 10
cases conﬁrm that these bacteria can be responsible for asymptomatic and short
colonizations, as well as for infections.
